Search | Clinical Trials Finder

Conditions: Coronary Artery Disease
Interventions: Clopidogrel, Placebo; Drug
Lead sponsor: Deutsches Herzzentrum Muenchen; Other
Eligibility: 18 Years and older
Enrollment: 4,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Multiple Myeloma
Interventions: CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 16
States / cities: Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Stroke
Interventions: Full-pressure ECP, Sham-pressure ECP; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 3
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California

Conditions: Venous Thrombosis
Interventions: Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 73
States / cities: Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Povetacicept; Drug
Lead sponsor: Alpine Immune Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more

Conditions: Healthy Volunteers
Interventions: AZD4831; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions: OPC-108459, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more

Conditions: Pulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more

Conditions: Subacute Myocardial Infarction
Interventions: Liposuction and stem cell implantation; Procedure
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions: AVP-923; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 39
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more

Conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
Interventions: Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB; Device
Lead sponsor: SurModics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 50
States / cities: Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 45 more

Conditions: Thrombosis
Interventions: BMS-986141, Aspirin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 21 more

Conditions: Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma
Interventions: Dalteparin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: ramipril, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 39
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 33 more

Conditions: Acute Aortic Dissection
Interventions: AMDS; Device
Lead sponsor: Artivion Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Acute Ischemic Stroke
Interventions: Active Stimulation, Sham Stimulation; Device
Lead sponsor: BrainsGate; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Arteriovenous Fistula
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 41 more

Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Alessandro Doria; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Cardiac Rhythm Disorder, Bradycardia
Interventions: Aveir VR Leadless Pacemaker System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 32 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: LCZ696, Valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 4,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 110
States / cities: Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more

Conditions: Hypertension, Pulmonary
Interventions: Ambrisentan - low dose, Ambrisentan - high dose; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Stroke, Ischemic Stroke
Interventions: "Hopkins" post tPA for ischemic stroke monitoring protocol; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Reversal of Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more

Search by objective public record fields.

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

Study to Assess Safety & Effects of Autologous ADSCs During Recovery Phase of ST-Elevation MI Effects of Autologous ADSC Implantation During Subacute Recovery Phase of ST-Elevation Myocardial Infarction

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Dalteparin in Preventing DVT in Participants With Cancer

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Efficacy and Safety of Ambrisentan in Children 8-18yrs

Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)